Page last updated: 2024-08-16

thalidomide and s 1033

thalidomide has been researched along with s 1033 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A	1
Lai, B; Mu, Q; Ouyang, G; Sheng, L; Wang, Y; Xu, K; Zhang, Y; Zhu, H	1

Reviews

2 review(s) available for thalidomide and s 1033

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
[Novel medical treatment modalities in hematology]. Ugeskrift for laeger, 2008, Jun-09, Volume: 170, Issue:24 Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine	2008

Article

Year

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.

Drug discovery today, 2016, Volume: 21, Issue:4

Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

[Novel medical treatment modalities in hematology].

Ugeskrift for laeger, 2008, Jun-09, Volume: 170, Issue:24

Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine

2008

Other Studies

1 other study(ies) available for thalidomide and s 1033

Article	Year
Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: A case report. Medicine, 2018, Volume: 97, Issue:14 Topics: Acute Disease; Antineoplastic Agents; Drug Therapy, Combination; Humans; Induction Chemotherapy; Lenalidomide; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maintenance Chemotherapy; Male; Middle Aged; Phenotype; Philadelphia Chromosome; Pyrimidines; Thalidomide	2018

Article

Year

Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: A case report.

Medicine, 2018, Volume: 97, Issue:14

Topics: Acute Disease; Antineoplastic Agents; Drug Therapy, Combination; Humans; Induction Chemotherapy; Lenalidomide; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maintenance Chemotherapy; Male; Middle Aged; Phenotype; Philadelphia Chromosome; Pyrimidines; Thalidomide

2018